Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Net Cash Flow (2023 - 2025)

Zenas BioPharma has reported Net Cash Flow over the past 3 years, most recently at -$4.9 million for Q4 2025.

  • Quarterly results put Net Cash Flow at -$4.9 million for Q4 2025, up 87.8% from a year ago — trailing twelve months through Dec 2025 was -$208.9 million (down 179.53% YoY), and the annual figure for FY2025 was -$208.9 million, down 179.53%.
  • Net Cash Flow for Q4 2025 was -$4.9 million at Zenas BioPharma, down from $71.5 million in the prior quarter.
  • Over the last five years, Net Cash Flow for ZBIO hit a ceiling of $176.2 million in Q3 2024 and a floor of -$152.3 million in Q2 2025.
  • Median Net Cash Flow over the past 3 years was -$15.4 million (2023), compared with a mean of $4.3 million.
  • Peak annual rise in Net Cash Flow hit 87.8% in 2025, while the deepest fall reached 524.31% in 2025.
  • Zenas BioPharma's Net Cash Flow stood at -$15.4 million in 2023, then crashed by 163.43% to -$40.4 million in 2024, then soared by 87.8% to -$4.9 million in 2025.
  • The last three reported values for Net Cash Flow were -$4.9 million (Q4 2025), $71.5 million (Q3 2025), and -$152.3 million (Q2 2025) per Business Quant data.